| 摘要: |
| 目的 探讨奥沙利铂（OXA）联合替吉奥胶囊一线治疗晚期食管癌的疗效及不良反应。方法 将35 例采用OXA联合替吉奥胶囊（SOX 方案）化疗的晚期食管癌患者设为治疗组，32 例行顺铂（DDP）联合氟尿嘧啶（DF 方案）化疗的患者设为对照组。观察及随访两组患者的近、远期疗效及不良反应。结果 治疗组及对照组的近期有效率分别为62.9%和37.5%，比较有统计学差异（P＜0.05），疾病控制率分别为85.7%和65.6%，组间比较无统计学差异（P＞0.05）。治疗组的中位生存期（12.4 个月）与对照组（10.4 个月）相比有统计学差异（P＜0.05），两组患者1年生存率分别为54.3%和34.4%，2 年生存率分别为5.7%和0.0%，两组间均无统计学差异（字2=2.680、2.654，均P＞0.05）。在不良反应方面，两组患者的血液学、消化道不良反应及肝功能损害比较无统计学差异（均P＞0.05），治疗组神经系统不良反应发生率高于对照组（P＜0.05）。结论 OXA 联合替吉奥（SOX 方案）治疗晚期食管癌疗效较为肯定，患者耐受良好。 |
| 关键词: 食管肿瘤 化疗 奥沙利铂 替吉奥 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Oxaliplatin combined with S-1 capsule as first-line therapy for advanced esophageal cancer |
|
ZHOU Taoqi, XIE Guoming, Zheng Hongyu, CHENG Ke, XU Caihong, ZHUANG Qi
|
|
Yinzhou Hospital Affiliated to Medicine School of Ningbo University
|
| Abstract: |
| Objective To investigate the efficacy of oxaliplatin combined with S-1 capsule (Tegafur, Gimeracil and Oteracil Potassium Capsules) as first-line therapy for patient with advanced esophageal cancer. Methods Sixty seven patients with advanced esophageal cancer were treated with two different regimes: 35 patients receiving SOX (oxaliplatin plus S-1 capsule) as study group, and 32 patients receiving DF(cisplatin plus fluorouracil) as control group. The short-term, long-termefficacy and adverse reactions were observed and compared between two groups. Results The short-termeffective rate of study group was higher than that of control group (62.9% vs 37.5%, P＜0.05), and there was no significant difference in disease control rate between two groups (85.7% vs 65.6%, P ＞0.05). The median survival time of study group was longer than that of control group (12.4 months vs 10.4 months, P＜0.05). The 1-y survival rates were 54.3% and 34.4%, 2-y survival rates were 5.7% and 0.0% in two groups, respectively (x2=2.680, 2.654, both P ＞0.05). There were no significant differences in the toxicity of hematopoietic system, gastrointestinal system and liver(P＞0.05); the neurotoxicity incidence of SOX regime was higher than that of DF regime (P＜0.05). Conclusion Oxaliplatin combined with S-1 capsule is an effective and well-tolerated chemotherapy regime for advanced esophageal cancer. |
| Key words: Esophageal cancer Chemotherapy Oxaliplatin S-1 |
